CSK Antibody (YA4803)

CSK (C-terminal Src kinase) is a non-receptor tyrosine kinase that functions as a central negative regulator of Src family kinases (SFKs) through phosphorylation of their conserved C-terminal inhibitory tyrosine residue, thereby maintaining controlled intracellular tyrosine kinase signaling and suppressing excessive SFK activity^[1]. Mechanistically, CSK is recruited to membrane-associated signaling complexes through interactions mediated by its SH2 domain, and this localization enables efficient regulation of SFK-dependent pathways involved in cell proliferation, differentiation, migration, immune signaling, and survival^[1][2]. Disruption of the CSK-centered regulatory network, including alterations in scaffold proteins such as Cbp/PAG1 and associated phosphatase systems, can result in sustained SFK activation, a molecular feature frequently observed in cancer and other pathological conditions^[1]. Experimental studies further demonstrate that loss of CSK function causes constitutive activation of SFKs in vivo, highlighting its essential role in maintaining signaling homeostasis during development and tissue regulation^[1]. Compared with the closely related isoform CHK (CSK-homologous kinase), CSK functions as a highly specific kinase for the inhibitory C-terminal regulatory site of SFKs, whereas CHK exhibits distinct inhibitory properties and mechanistic characteristics despite sharing the common role of SFK suppression^[3]. For experimental applications, CSK is widely used as a molecular tool for investigating SFK signaling, kinase regulation, immune receptor pathways, and oncogenic tyrosine kinase networks, while small-molecule CSK inhibitors remain relatively limited compared with the extensive pharmacological targeting of SFKs themselves^[2][4].